China Meheco Group (SHA:600056) received a drug registration certificate for tedisamil phosphate tablets from the Chinese drug administration, according to a Shanghai bourse disclosure on Thursday.

The drug is primarily used for the treatment of acute bacterial skin and skin structure infections.

The pharmaceutical company invested approximately 16.4 million yuan into the research and development of the project, the disclosure said.